Tag: nerinetide
NoNO announces first patient dosed with NoNO-42 in Phase 1 study
NoNO Inc has announced the dosing of the first participant in its Phase 1 clinical trial evaluating NoNO-42—a next-generation neuroprotective drug developed in the...
LINNC 2021: ESCAPE-NEXT trial may bring “dream” of combining neuroprotection with...
At this year’s LINNC Paris Course (14–16 September, Paris, France and virtual), audiences heard that the ESCAPE-NEXT trial (sponsored by NoNO Inc.), which has already started enrolling...
